document.getElementById('index-articles-list').innerHTML = `
  • First-in-Human Single and Multiple Ascending Dose Studies of Balinatunfib, a Small Molecule Inhibitor of TNFR1 Signaling in Healthy Participants

    Nassr Nassr,Faiza Rharbaoui,Dietmar Weitz et al.

    Clinical pharmacology and therapeutics. 2025 Mar 30. DOI:10.1002/cpt.3655
  • Frequency and Nature of Generic "Design Around" of Brand-Name Patents in the United States
    在美国品牌专利的通用"规避设计"的频率和性质

    Janet Freilich,Aaron S Kesselheim

    Clinical pharmacology and therapeutics. 2025 Mar 27. DOI:10.1002/cpt.3659
  • Hepatic Impairment and the Differential Effects on Drug Clearance Mechanisms: Analysis of Pharmacokinetic Changes in Disease State
    肝功能损害及对药物清除机制的不同影响：疾病状态下药代动力学变化的分析

    Lloyd Wei Tat Tang,Manthena V S Varma

    Clinical pharmacology and therapeutics. 2025 Mar 26. DOI:10.1002/cpt.3643
  • Impact of Model-Informed Drug Development on Drug Development Cycle Times and Clinical Trial Cost
    模型引导的药物开发对药物研发周期及临床试验成本的影响

    Vaishali Sahasrabudhe,Timothy Nicholas,Gianluca Nucci et al.

    Clinical pharmacology and therapeutics. 2025 Mar 26. DOI:10.1002/cpt.3636
  • Impact of Age and Factor Xa Inhibitor Concentrations on Bleeding Risk in Patients with Atrial Fibrillation
    年龄和因子Xa抑制剂浓度对房颤患者出血风险的影响

    Shin-Yi Lin,Yen-Bing Liu,Li-Ting Ho et al.

    Clinical pharmacology and therapeutics. 2025 Mar 25. DOI:10.1002/cpt.3654
    • `; document.getElementById('index-articles-more').href = `https://i.iikx.com/journal/1532-6535.html`; document.getElementById('index-articles-more').innerHTML='更多内容'; document.getElementById('index-articles-more').style="float:right;background:var(--primary-color);color:#fff;font-size:13px;border-radius:5px;padding:0px 10px;margin-right:5px;line-height:1.7"; document.getElementsByClassName('index-artcles')[0].style.display = 'block'; document.getElementById('showJournalIndexUrl').style.display = 'block'; document.querySelector('#showJournalIndexUrl a').href = `https://i.iikx.com/journal/1532-6535.html`;